Try our mobile app

Switch to company model in classical logic    *

General information

Country: NETHERLANDS

Sector: Biotechnology

argenx SE operates as a biotechnology company. The Company develops antibody based therapies for the treatment of severe autoimmune diseases and cancer. argenx serves customers in the Netherlands and Belgium.
Website: argenx.com



Growth: Good revenue growth rate >200%, there is acceleration compared to average historical growth rates 67.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -39.3%. On average the margin is decreasing steadily. Gross margin is high, +100.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 67% of quarters (showing a gain of +$0.47 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 2.9% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 183.1% higher than minimum and 9.4% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 37.2x by EV / Sales multiple , the company can be 15.9% overvalued

Key Financials (Download financials)

Ticker: ARGX
Share price, USD:  (-0.3%)959.49
year average price 865.19  


year start price 711.62 2025-09-27

min close price 711.62 2025-09-27

max close price 1058.90 2026-08-27

current price 959.49 2026-09-26
Common stocks: 47 341 929

Dividend Yield:  0.0%
EV / Sales: 44.2x
Margin (EBITDA LTM / Revenue): -39.3%
Fundamental value created in LTM:
Market Cap ($m): 45 553
Net Debt ($m): -1 323
EV (Enterprise Value): 44 230
Price to Book: 7.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-13globenewswire.com

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

2026-01-12seekingalpha.com

argenx SE (ARGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-05globenewswire.com

argenx Announces Leadership Transition Marking Next Evolution of Growth

2025-12-15globenewswire.com

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease

2025-11-26seekingalpha.com

argenx: Sights Set On $1,000

2025-11-16seekingalpha.com

PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors

2025-11-06seekingalpha.com

Baron International Growth Fund Q3 2025 Contributors And Detractors

2025-10-27seekingalpha.com

Baron Health Care Fund Q3 2025 Top Contributors And Detractors

2025-09-12seekingalpha.com

argenx: Bullish On This R&D Focused Biotech Stock

2025-09-08seekingalpha.com

Argenx SE (ARGX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q2 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD EUR
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-07-31 2025-03-31 2024-09-30 2024-06-30 2024-03-21 2023-09-30 2023-06-30 2023-03-31 2022-09-30
acceptedDate 2025-07-31 08:16:12 2025-03-31 00:00:00 2025-03-20 06:46:51 2024-09-30 00:00:00 2024-06-28 20:00:00 2024-03-21 06:07:09 2024-03-21 06:22:26 2023-09-29 20:00:00 2023-06-30 00:00:00 2023-03-31 00:00:00 2023-03-16 16:26:06 2022-09-30 00:00:00 2022-03-21 12:56:27 2021-03-30 16:55:53
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 948M 791M 2 190M 573M 877M 401M 1 226M 330M 271M 219M 411M 138M 497M 41M
costOfRevenue 111M 81M 227M 59M 52M 43M 118M 36M 24M 18M 29M 10M 0 0
grossProfit 837M 710M 1 963M 514M 825M 358M 1 108M 294M 247M 201M 381M 128M 497M 41M
grossProfitRatio 0.883 0.898 0.897 0.94 0.892 0.891 0.911 0.916 0.926
researchAndDevelopmentExpenses 328M 309M 983M 236M 447M 225M 859M 192M 196M 166M 663M 237M 581M 370M
generalAndAdministrativeExpenses 423M 0 745M 0 0 0 507M 0 0 0 354M 0 246M 171M
sellingAndMarketingExpenses 178M 0 307M 0 0 0 202M 0 0 0 116M 0 60M 0
sellingGeneralAndAdministrativeExpenses 601M 276M 1 055M 278M 490M 236M 710M 192M 161M 149M 470M 108M 306M 171M
otherExpenses -293M -14M -54M -14M -10M 0 -36M 0 0 -11M -32M -9M -40M -22M
operatingExpenses 636M 571M 1 985M 500M 936M 449M 1 534M 374M 347M 304M 1 102M 336M 846M 519M
costAndExpenses 747M 652M 2 212M 559M 523M 493M 1 651M 410M 371M 323M 1 131M 347M 846M 519M
interestIncome 38M 37M 138M 41M 39M 39M 93M 30M 20M 17M 25M 8M 3M 5M
interestExpense 1M 1M 2M 676 000 572 000 512 000 904 000 231 000 207 000 188 000 2M 785 000 1M 403 657
depreciationAndAmortization 13M 0 18M 75M 9M 24M 111M 30M 20M 17M 104M 8M 6M 4M
ebitda 514M 203M 105M 89M -37M -55M -192M -51M -82M -87M -623M -201M -393M -601M
ebitdaratio 0.542 0.257 0.155 -0.042 -0.136 -0.153 -0.302 -0.398 -1.454
operatingIncome 201M 139M -22M 14M -159M -93M -425M -81M -102M -104M -720M -209M -349M -478M
operatingIncomeRatio 0.212 0.176 0.025 -0.181 -0.233 -0.244 -0.377 -0.473 -1.512
totalOtherIncomeExpensesNet 86M 63M 107M 74M 144M -21M 121M -33M -4M 28M -9M -32M -51M -128M
incomeBeforeTax 287M 202M 85M 88M -15M -74M -304M -83M -84M -76M -729M -241M -400M -605M
incomeBeforeTaxRatio 0.303 0.256 0.154 -0.017 -0.185 -0.253 -0.31 -0.348 -1.747
incomeTaxExpense 42M 33M -748M -3M -44M -13M -9M -11M 11M -47M -20M -6M 9M 3M
netIncome 245M 169M 833M 91M -32M -62M -295M -73M -94M -29M -710M -235M -408M -608M
netIncomeRatio 0.259 0.214 0.159 -0.037 -0.154 -0.22 -0.349 -0.132 -1.703
eps 6.85 2.78 13.92 1.52 -0.55 -1.04 -5.16 -1.25 -1.69 -0.52 -13.05 -4.26 -7.99 -13.4
epsdiluted 6.37 2.58 1.39 -0.55 -1.04 -1.25 -1.69 -0.52 -4.26
weightedAverageShsOut 61M 61M 60M 60M 59M 59M 57M 58M 56M 56M 54M 55M 51M 45M
weightedAverageShsOutDil 66M 66M 65M 66M 59M 59M 57M 58M 56M 56M 54M 55M 51M 45M
link Link Link
finalLink Link Link
filingDate 2025-03-20 2024-03-21 2023-03-16 2022-03-21 2021-03-30
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 136M 92M 23M 2M 5M
ebit 88M -304M -727M -399M -605M
nonOperatingIncomeExcludingInterest -109M -121M 7M 50M 127M
netIncomeFromContinuingOperations 833M -295M -710M -408M -608M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 1M 0 0 0 0
bottomLineNetIncome 832M -295M -710M -408M -608M
epsDiluted 12.78 -5.16 -13.05 -7.99 -13.4

Balance Sheet Statement

Property 2025 q2 2024 q4 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q2 2021 q4 2020 q4
date 2025-06-30 2024-12-31 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-15 2022-12-31 2022-06-30 2021-12-31 2020-12-31
symbol ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD EUR
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-07-31 2024-06-30 2024-03-21 2023-09-30 2023-06-30 2023-03-16 2022-06-30
acceptedDate 2025-07-31 08:16:12 2025-03-20 06:46:51 2024-06-28 20:00:00 2024-03-21 06:07:09 2024-03-21 06:22:26 2023-09-29 20:00:00 2023-06-30 00:00:00 2023-03-16 08:21:17 2023-03-16 16:26:06 2022-06-30 00:00:00 2022-03-21 12:56:27 2021-03-30 16:55:53
calendarYear 2025 2024 2024 2023 2023 2023 2022
period Q2 FY Q2 Q1 FY Q3 Q2 Q1 FY Q2 FY FY
cashAndCashEquivalents 2 086M 1 500M 1 438M -2 947M 2 049M -1 889M 1 111M 0 801M 1 367M 1 335M 1 217M
shortTermInvestments 1 842M 1 879M 1 664M 5 894M 1 131M 3 778M 886M 0 1 392M 1 230M 1 002M 780M
cashAndShortTermInvestments 3 928M 3 379M 3 102M 2 947M 3 180M 1 889M 1 997M 0 2 193M 2 597M 2 337M 1 996M
netReceivables 1 198M 909M 656M 0 499M 0 355M 0 277M 114M 38M 7M
inventory 341M 407M 326M 0 311M 0 201M 0 228M 136M 109M 25M
otherCurrentAssets 363M 0 179M 0 0 0 139M 0 0 82M 0 0
totalCurrentAssets 5 830M 4 883M 4 264M 2 947M 4 124M 1 889M 2 692M 0 2 774M 2 929M 2 543M 2 057M
propertyPlantEquipmentNet 46M 44M 37M 0 23M 0 15M 0 16M 14M 16M 12M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 219M 181M 142M 0 125M 0 190M 0 175M 171M 172M 167M
goodwillAndIntangibleAssets 219M 181M 142M 0 125M 0 190M 0 175M 171M 172M 167M
longTermInvestments 11M 50M 132M 0 47M 0 50M 0 40M 41M 53M 6M
taxAssets 900M 924M 175M 0 97M 0 139M 0 79M 54M 32M 15M
otherNonCurrentAssets 171M 120M 47M -2 947M 126M -1 889M 109M 0 49M 39M 34M 22M
totalNonCurrentAssets 1 346M 1 319M 533M -2 947M 419M -1 889M 502M 0 360M 320M 307M 222M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 7 176M 6 203M 4 797M 0 4 542M 0 3 194M 0 3 134M 3 249M 2 850M 2 279M
accountPayables 532M 342M 281M 0 246M 0 195M 0 189M 167M 209M 206M
shortTermDebt 8M 7M 6M 0 5M 0 3M 0 3M 3M 4M 3M
taxPayables 18M 13M 14M 0 4M 0 5M 0 3M 3M 4M 3M
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 46M
otherCurrentLiabilities 484M 157M 199M 0 73M 0 119M 0 23M 94M 828 000 0
totalCurrentLiabilities 1 042M 670M 500M 0 423M 0 318M 0 302M 265M 301M 328M
longTermDebt 36M 0 28M 0 0 0 8M 0 0 6M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 269M
deferredTaxLiabilitiesNonCurrent 0 0 5M 0 5M 0 9M 0 8M 8M 6M 1M
otherNonCurrentLiabilities 2M 2M 2M 0 1M 0 1M 0 870 000 -156M 417 000 155 999
totalNonCurrentLiabilities 38M 34M 35M 0 22M 0 18M 0 18M 14M 15M 277M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 36M 33M 34M 0 15M 0 11M 0 9M 10M 8M 6M
totalLiabilities 1 080M 704M 534M 0 445M 0 336M 0 321M 279M 316M 605M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 7M 7M 7M 0 6M 0 7M 0 7M 7M 6M 6M
retainedEarnings -1 157M -1 572M -2 437M 0 -2 405M 0 -2 233M 0 -2 110M -1 836M -1 400M -992M
accumulatedOtherComprehensiveIncomeLoss 78M 67M 945M 3 797M 72M 2 703M 710M 0 72M 527M 465M 321M
othertotalStockholdersEquity 7 167M 5 747M 0 0 4 374M 0 4 272M
totalStockholdersEquity 6 096M 5 498M 4 262M 3 797M 4 098M 2 703M 2 858M 0 2 814M 2 970M 2 534M 1 674M
totalEquity 6 096M 5 498M 4 262M 3 797M 4 098M 2 703M 2 858M 0 2 814M 2 970M 2 534M 1 674M
totalLiabilitiesAndStockholdersEquity 7 176M 4 797M 3 797M 2 703M 3 194M 0 3 249M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 7 176M 6 203M 4 797M 3 797M 4 542M 2 703M 3 194M 0 3 134M 3 249M 2 850M 2 279M
totalInvestments 1 853M 1 929M 1 796M 5 894M 1 178M 3 778M 936M 0 1 432M 1 272M 1 055M 786M
totalDebt 43M 39M 34M 0 20M 0 11M 0 12M 10M 11M 10M
netDebt -2 043M -1 461M -1 404M 2 947M -2 029M 1 889M -1 099M 0 -788M -1 358M -1 323M -1 204M
link Link Link Link
finalLink Link Link Link
filingDate 2025-03-20 2024-03-21 2023-03-16 2022-03-21 2021-03-30
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 818M 418M 241M 28M 287 000
otherReceivables 91M 81M 36M 10M 7M
prepaids 188M 134M 76M 59M 28M
totalPayables 356M 250M 192M 213M 210M
otherPayables 13M 4M 3M 4M 3M
accruedExpenses 151M 95M 84M 84M 69M
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 33M 15M 9M 8M 6M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 5 949M 5 651M 4 310M 3 463M 2 339M
otherTotalStockholdersEquity 1 047M 772M 535M 0 0

Cash Flow Statement

Property 2025 q2 2024 q4 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2022 q4 2021 q4 2020 q4 2020 q3 2014 q2 2014 q1
date 2025-06-30 2024-12-31 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2022-12-31 2021-12-31 2020-12-31 2020-09-30 2014-06-30 2014-03-31
symbol ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX
reportedCurrency USD USD USD USD USD USD USD USD USD EUR EUR EUR EUR
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-07-31 2024-06-30 2024-03-21 2023-09-30 2023-06-30 2020-09-30 2014-06-30 2014-03-31
acceptedDate 2025-07-31 08:16:12 2025-03-20 06:46:51 2024-06-28 20:00:00 2024-03-21 06:07:09 2024-03-21 06:22:26 2023-09-29 20:00:00 2023-06-29 20:00:00 2023-03-16 16:26:06 2022-03-21 12:56:27 2021-03-30 16:55:53 2020-09-29 20:00:00 2014-06-30 00:00:00 2014-03-31 00:00:00
calendarYear 2025 2024 2024 2023 2023 2020 2014 2014
period Q2 FY Q2 Q1 FY Q3 Q2 FY FY FY Q3 Q2 Q1
netIncome 418M 833M 29M -62M -425M -73M -123M -720M -349M -478M -158M -4M -3M
depreciationAndAmortization 13M 18M 9M 0 111M 0 5M 104M 5M 4M 0 31 158 27 507
deferredIncomeTax 0 0 0 0 0 0 0 0 0 0 0 0 0
stockBasedCompensation 0 235M 102M 0 233M 0 0 157M 179M 97M 0 466 280 38 509
changeInWorkingCapital -129M -325M -101M 0 -309M 0 -163M -376M -341M -28M 0 4M -673 910
accountsReceivables -363M -422M 0 0 -186M 0 -68M -222M -32M 22M 0 0 0
inventory 35M -96M 0 0 -83M 0 27M -119M -84M -24M 0 0 0
accountsPayables 362M 246M 77M 0 0 0 -617 005 0 0 0 0 0 0
otherWorkingCapital -164M -52M -177M 0 -40M 0 -122M -35M -225M -26M 0 4M -66 016
otherNonCashItems 136M -844M -115M 62M -31M 73M 23M -28M -101M 7M 158M 0 0
netCashProvidedByOperatingActivities 438M -83M -76M 0 -420M 0 -258M -863M -607M -398M 0 310 943 -3M
investmentsInPropertyPlantAndEquipment -49M -2M -22M 0 -812 000 0 -479 781 -837 000 -4M -1M 0 -42 282 -1375.327
acquisitionsNet 0 -7M 0 0 -13M 0 0 -2M 0 0 0 0 0
purchasesOfInvestments -1 124M -2 184M -1 107M 0 -1 272M 0 -281M -1 694M -228M 0 0 0 0
salesMaturitiesOfInvestments 1 164M 1 430M 568M 0 1 544M 0 782M 1 326M 0 0 0 0 0
otherInvestingActivites 0 0 0 0 -1 0 40 543 48 136
netCashUsedForInvestingActivites -10M -561M 0 0 500M 0 -1739.413 46 761
debtRepayment -1M 0 0 0 0 0 0 0
commonStockIssued 0 45M 0 0 65M 0 0 0
commonStockRepurchased -5M 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0
otherFinancingActivites -5M -5M 0 0 -3M 0 0 0
netCashUsedProvidedByFinancingActivities 74M 40M 0 0 62M 0 0 0
effectOfForexChangesOnCash 84M -28M 0 0 23M 0 -41M -54M -50M 65M 0 20 464 0
netChangeInCash 586M -549M -611M 0 1 248M 0 264M -534M 118M 845M 0 80 364 -3M
cashAtEndOfPeriod 2 086M 1 500M 1 438M 0 2 049M 0 1 111M 801M 1 335M 1 217M 0 28M 28M
cashAtBeginningOfPeriod 1 500M 2 049M 2 049M 0 801M 0 847M 1 335M 1 217M 372M 0 28M 31M
operatingCashFlow 438M -83M -76M 0 -420M 0 -258M -863M -607M -398M 0 310 943 -3M
capitalExpenditure -5M -68M -22M 0 -44M 0 -479 781 -104M -121M -5M 0 -42 282 -1375.327
freeCashFlow 433M -151M -98M 0 -464M 0 -259M -967M -728M -404M 0 268 661 -3M
link Link Link
finalLink Link Link
filingDate 2025-03-20 2024-03-21 2023-03-16 2022-03-21 2021-03-30
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 45M 50M -90M -115M 346M
netCashProvidedByInvestingActivities -718M 308M -461M -347M 345M
netDebtIssuance -8M -4M -4M -4M -3M
longTermNetDebtIssuance -8M -4M -4M -4M -3M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 309M 1 197M 761M 1 091M 813M
netCommonStockIssuance 309M 1 197M 761M 1 091M 813M
commonStockIssuance 309M 1 197M 761M 1 091M 813M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -21M 144M 87M 32M 22M
netCashProvidedByFinancingActivities 280M 1 337M 844M 1 120M 833M
incomeTaxesPaid 0 0 0 0 0
interestPaid 378 397 0 0 0 0

Earning call transcript

2025 q3
2025-10-30 ET (fiscal 2025 q3)
2025 q2
2025-07-31 ET (fiscal 2025 q2)
2025 q1
2025-05-08 ET (fiscal 2025 q1)
2024 q4
2025-02-27 ET (fiscal 2024 q4)
2024 q3
2024-10-31 ET (fiscal 2024 q3)
2024 q2
2024-07-25 ET (fiscal 2024 q2)
2024 q1
2024-05-09 ET (fiscal 2024 q1)
2023 q4
2024-02-29 ET (fiscal 2023 q4)
2023 q3
2023-10-31 ET (fiscal 2023 q3)
2023 q2
2023-07-27 ET (fiscal 2023 q2)
2023 q1
2023-05-06 ET (fiscal 2023 q1)
2022 q4
2023-03-02 ET (fiscal 2022 q4)
2022 q2
2022-07-28 ET (fiscal 2022 q2)
2022 q1
2022-05-07 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-07-23 05:00 ET
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
2026-07-16 05:00 ET
argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
2026-06-23 ET
argenx to Host Autoimmune Myositis R&D Webinar
2026-06-03 ET
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
2026-05-28 ET
argenx to Host Myositis R&D Webinar on June 23, 2026
2026-05-27 ET
argenx to Present at Upcoming Investor Conferences
2026-05-08 ET
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
2026-05-07 05:00 ET
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-06 20:30 ET
argenx to Present at BofA Securities 2026 Health Care Conference
2026-05-06 20:01 ET
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
2026-04-30 05:00 ET
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
2026-04-18 05:00 ET
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
2026-03-20 ET
argenx announces Annual General Meeting of Shareholders on May 6, 2026
2026-03-06 ET
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
2026-02-26 ET
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
2026-02-26 ET
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
2026-02-23 ET
argenx to Present at TD Cowen 46th Annual Healthcare Conference
2026-02-19 ET
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
2026-01-13 ET
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
2026-01-12 ET
argenx Highlights 2026 Strategic Priorities
2026-01-06 ET
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
2026-01-05 ET
argenx Announces Leadership Transition Marking Next Evolution of Growth
2025-12-15 ET
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
2025-11-18 ET
argenx Announces Results of Extraordinary General Meeting of Shareholders
2025-10-30 06:00 ET
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-10-29 ET
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
2025-10-23 ET
argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
2025-10-15 ET
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
2025-10-03 ET
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
2025-08-28 ET
argenx to Present at Upcoming Investor Conferences
2025-08-25 ET
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
2025-08-19 ET
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
2025-08-12 ET
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
2025-07-31 ET
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
2025-07-24 ET
argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
2025-06-30 ET
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
2025-06-20 ET
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
2025-06-10 ET
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
2025-06-03 ET
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
2025-05-28 ET
argenx Announces Results of Annual General Meeting of Shareholders
2025-05-08 ET
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
2025-05-06 ET
argenx to Present at BofA Securities 2025 Health Care Conference
2025-05-01 ET
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
2025-04-28 ET
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2025-04-11 ET
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
2025-04-10 ET
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
2025-04-08 ET
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
2025-03-07 ET
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
2025-02-27 ET
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
2025-02-25 ET
argenx to Present at TD Cowen 45th Annual Healthcare Conference
2025-02-20 ET
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
2025-01-13 ET
argenx Highlights 2025 Strategic Priorities
2025-01-06 ET
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
2024-12-27 ET
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
2024-11-26 ET
argenx to Present at Upcoming Investor Conferences
2024-11-20 ET
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
2024-11-11 ET
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
2024-11-11 ET
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
2024-11-05 ET
argenx to Participate at Upcoming Investor Conferences
2024-10-31 06:00 ET
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
2024-10-24 05:00 ET
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
2024-10-15 05:00 ET
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
2024-09-19 05:00 ET
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
2024-07-25 05:00 ET
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
2024-07-18 05:00 ET
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
2024-07-16 04:30 ET
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
2024-07-16 04:15 ET
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
2024-06-25 20:30 ET
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
2024-06-21 20:50 ET
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
2024-06-17 05:00 ET
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
2024-06-04 05:00 ET
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-09 05:00 ET
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
2024-05-07 21:30 ET
argenx announces results of Annual General Meeting of Shareholders
2024-05-07 05:00 ET
argenx to Present at BofA Securities 2024 Health Care Conference
2024-05-02 05:00 ET
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
2024-04-16 05:00 ET
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
2024-03-27 06:00 ET
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
2024-03-26 20:00 ET
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
2024-03-26 06:00 ET
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
2024-03-07 21:01 ET
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
2024-02-29 06:00 ET
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
2024-02-26 06:00 ET
argenx to Present at Upcoming Investor Conferences
2024-02-22 06:00 ET
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
2024-02-20 06:00 ET
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
2024-01-18 06:00 ET
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
2024-01-08 06:00 ET
argenx Highlights 2024 Strategic Priorities
2024-01-02 06:00 ET
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-20 06:00 ET
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
2023-11-28 06:00 ET
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
2023-11-16 12:40 ET
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
2023-11-01 06:00 ET
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
2023-11-01 06:00 ET
argenx to Present at Upcoming Investor Conferences
2023-10-31 06:00 ET
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-10-24 05:00 ET
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
2023-09-21 05:00 ET
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
2023-09-15 05:00 ET
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
2023-08-30 05:00 ET
argenx to Present at Upcoming Investor Conferences
2023-07-27 05:00 ET
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
2023-07-24 20:30 ET
argenx announces closing of global offering
2023-07-20 05:00 ET
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
2023-07-19 21:58 ET
argenx announces full exercise of underwriters’ option to purchase additional ADSs
2023-07-19 01:30 ET
argenx raises $1.1 billion in gross proceeds in a global offering
2023-07-18 ET
argenx raises $1.1 billion in gross proceeds in a global offering
2023-07-17 20:01 ET
argenx announces launch of proposed global offering
2023-07-17 05:00 ET
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
2023-06-30 13:39 ET
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
2023-06-20 22:12 ET
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
2023-06-20 05:00 ET
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
2023-05-31 05:00 ET
argenx to Present at Upcoming Investor Conferences
2023-05-04 05:00 ET
argenx Reports First Quarter 2023 Financial Results and Provides Business Update
2023-05-03 20:01 ET
argenx announces results of Annual General Meeting of Shareholders
2023-05-02 05:00 ET
argenx to Present at BofA Securities 2023 Health Care Conference
2023-04-27 05:00 ET
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
2023-04-18 05:00 ET
argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting
2023-04-17 06:00 ET
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
2023-03-17 20:01 ET
argenx Announces Annual General Meeting of Shareholders on May 2, 2023
2023-03-15 13:25 ET
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
2023-03-02 06:00 ET
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
2023-03-02 06:00 ET
argenx Announces Planned Transition of Chief Operating Officer
2023-02-27 21:01 ET
argenx Appoints Steve Krognes to Board of Directors
2023-02-27 06:00 ET
argenx to Present at Upcoming Investor Conferences
2023-02-23 06:00 ET
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
2023-01-27 06:00 ET
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
2023-01-16 18:30 ET
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
2023-01-09 06:00 ET
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
2023-01-03 06:00 ET
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
2022-12-12 21:01 ET
argenx Appoints Ana Cespedes to Board of Directors
2022-12-10 16:30 ET
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
2022-11-30 06:00 ET
argenx Enters Into Agreement To Acquire Priority Review Voucher
2022-11-22 06:00 ET
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
2022-11-07 06:00 ET
argenx to Present at Upcoming Investor Conferences
2022-10-27 05:00 ET
argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
2022-10-20 05:00 ET
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
2022-09-21 05:00 ET
argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings
2022-09-21 05:00 ET
argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis
2022-09-08 18:10 ET
argenx Appoints Camilla Sylvest to Board of Directors
2022-08-31 05:00 ET
argenx to Present at Wells Fargo Healthcare Conference
2022-08-11 11:00 ET
argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis
2022-07-28 06:30 ET
argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
2022-07-28 05:00 ET
argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
2022-07-21 05:00 ET
argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022
2022-06-24 05:00 ET
argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe
2022-06-01 05:00 ET
argenx to Present at Upcoming Investor Conferences
2022-05-31 05:00 ET
argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis
2022-05-19 11:00 ET
argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases
2022-05-10 21:30 ET
argenx announces results of Annual General Meeting of Shareholders
2022-05-05 05:00 ET
argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
2022-05-05 05:00 ET
argenx Reports First Quarter 2022 Financial Results and Provides Business Update
2022-05-04 05:00 ET
argenx to Present at BofA Securities 2022 Healthcare Conference
2022-04-28 05:00 ET
argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022
2022-04-05 05:00 ET
argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting
2022-04-01 05:00 ET
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
2022-03-29 21:00 ET
argenx announces full exercise of underwriters’ option to purchase additional ADSs
2022-03-29 20:30 ET
argenx announces Annual General Meeting of Shareholders on May 10, 2022
2022-03-28 20:30 ET
argenx announces closing of global offering
2022-03-24 01:00 ET
argenx raises $700 million in gross proceeds in a global offering
2022-03-22 20:15 ET
argenx announces launch of proposed global offering
2022-03-22 06:00 ET
argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
2022-03-03 06:00 ET
argenx Reports Full Year 2021 Financial Results and Provides Fourth Quarter Business Update
2022-02-28 06:00 ET
argenx to Present at the 42nd Annual Cowen Health Care Conference
2022-02-24 06:00 ET
argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022
2022-02-10 06:00 ET
argenx to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2022-01-20 07:00 ET
argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia Gravis
2022-01-07 06:00 ET
argenx Highlights Strategic Priorities for 2022
2022-01-03 06:00 ET
argenx to Present at 40th Annual J.P. Morgan Healthcare Conference
2021-12-17 23:09 ET
Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
2021-12-17 22:09 ET
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
2021-11-10 06:00 ET
argenx to Present at Upcoming Investor Conferences
2021-10-28 05:00 ET
argenx Reports Third Quarter 2021 Financial Results and Provides Business Update
2021-10-21 05:00 ET
argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021
2021-10-08 05:00 ET
argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings
2021-09-03 05:00 ET
argenx to Present at Upcoming Investor Conferences
2021-08-25 05:00 ET
argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis
2021-08-04 05:00 ET
argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference
2021-07-29 05:00 ET
argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update
2021-07-22 05:00 ET
argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021
2021-07-14 05:00 ET
argenx to Host Virtual R&D Day on July 20, 2021
2021-06-16 22:30 ET
argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology
2021-06-07 05:00 ET
argenx to regain global rights to cusatuzumab
2021-06-01 08:01 ET
argenx Appoints Karl Gubitz as Chief Financial Officer
2021-06-01 05:00 ET
argenx to Present at Upcoming Investor Conferences
2021-05-14 05:00 ET
argenx Reports First Quarter 2021 Financial Results and Provides Business Update
2021-05-11 09:00 ET
argenx announces results of Annual General Meeting of Shareholders
2021-05-07 05:00 ET
argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021
2021-04-28 05:00 ET
argenx Management to Present at Upcoming Virtual Investor Conferences
2021-03-30 20:00 ET
argenx announces Annual General Meeting of Shareholders on May 11, 2021
2021-03-04 06:00 ET
argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update
2021-03-02 07:00 ET
argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis
2021-02-25 06:00 ET
argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021
2021-02-05 21:01 ET
argenx announces closing of global offering
2021-02-04 06:00 ET
argenx announces full exercise of underwriters’ option to purchase additional ADSs
2021-02-03 03:15 ET
argenx raises $1.0 billion in gross proceeds in a global offering
2021-02-02 14:37 ET
argenx Issues Statement Concerning Efgartigimod
2021-02-01 21:01 ET
argenx announces launch of proposed global offering
2021-02-01 06:00 ET
argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis
2021-01-08 06:00 ET
argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline
2021-01-06 21:01 ET
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
2021-01-06 21:01 ET
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
2020-11-23 06:00 ET
argenx Enters Into Agreement To Acquire Priority Review Voucher
2020-11-17 12:00 ET
argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience
2020-11-09 06:00 ET
argenx to Participate in Upcoming Virtual Investor Conferences
2020-10-22 05:00 ET
argenx Reports Third Quarter 2020 Financial Results and Provides Business Update
2020-10-15 05:00 ET
argenx to Report Third Quarter 2020 Financial Results and Business Update on October 22, 2020
2020-10-06 06:00 ET
argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships
2020-10-05 05:00 ET
argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session
2020-09-02 05:00 ET
argenx Management to Present at Upcoming Virtual Investor Conferences
2020-08-04 05:00 ET
argenx to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
2020-07-30 05:00 ET
argenx reports half year 2020 financial results and provides second quarter business update

SEC forms

Show financial reports only

SEC form 6
2026-08-27 20:19 ET
Argenx SE published news for 2026 q2
SEC form 6
2026-08-27 20:19 ET
Argenx SE published news for 2026 q2
SEC form 6
2026-08-17 12:54 ET
Argenx SE published news for 2026 q2
SEC form 6
2026-08-17 12:54 ET
Argenx SE published news for 2026 q2
SEC form 6
2026-08-17 12:54 ET
Argenx SE published news for 2026 q2
SEC form 6
2026-08-03 20:12 ET
Argenx SE published news for 2026 q2
SEC form 6
2026-08-03 20:12 ET
Argenx SE published news for 2026 q2
SEC form 6
2026-07-27 06:03 ET
Argenx SE published news for 2026 q2
SEC form 6
2026-07-27 06:03 ET
Argenx SE published news for 2026 q2
SEC form 6
2026-07-23 12:21 ET
Argenx SE published news for 2026 q2
SEC form 6
2026-07-23 12:21 ET
Argenx SE published news for 2026 q2
SEC form 6
2026-07-23 12:21 ET
Argenx SE published news for 2026 q2
SEC form 6
2026-07-23 12:21 ET
Argenx SE published news for 2026 q2
SEC form 6
2026-06-23 10:22 ET
Argenx SE published news for 2026 q1
SEC form 6
2026-06-23 10:22 ET
Argenx SE published news for 2026 q1
SEC form 6
2026-06-03 11:16 ET
Argenx SE published news for 2026 q1
SEC form 6
2026-06-03 11:16 ET
Argenx SE published news for 2026 q1
SEC form 6
2026-05-09 01:08 ET
Argenx SE published news for 2026 q1
SEC form 6
2026-05-09 01:08 ET
Argenx SE published news for 2026 q1
SEC form 6
2026-05-07 12:46 ET
Argenx SE published news for 2026 q1
SEC form 6
2026-05-07 12:46 ET
Argenx SE published news for 2026 q1
SEC form 6
2026-05-07 12:46 ET
Argenx SE published news for 2026 q1
SEC form 6
2026-05-06 20:28 ET
Argenx SE published news for 2026 q1
SEC form 6
2026-05-06 20:28 ET
Argenx SE published news for 2026 q1
SEC form 6
2026-04-20 10:02 ET
Argenx SE published news for 2026 q1
SEC form 6
2026-04-20 10:02 ET
Argenx SE published news for 2026 q1
SEC form 6
2026-03-20 20:24 ET
Argenx SE published news for 2025 q4
SEC form 6
2026-03-20 20:24 ET
Argenx SE published news for 2025 q4
SEC form 20
2026-03-19 10:13 ET
Argenx SE published news for 2025 q4
SEC form 20
2026-03-19 10:13 ET
Argenx SE published news for 2025 q4
SEC form 20
2026-03-19 10:13 ET
Argenx SE published news for 2025 q4
SEC form 20
2026-03-19 10:13 ET
Argenx SE published news for 2025 q4
SEC form 20
2026-03-19 10:13 ET
Argenx SE published news for 2025 q4
SEC form 20
2026-03-19 10:13 ET
Argenx SE published news for 2025 q4
SEC form 20
2026-03-19 10:13 ET
Argenx SE published news for 2025 q4
SEC form 20
2026-03-19 10:13 ET
Argenx SE published news for 2025 q4
SEC form 20
2026-03-19 10:13 ET
Argenx SE published news for 2025 q4
SEC form 20
2026-03-19 10:13 ET
Argenx SE published news for 2025 q4
SEC form 20
2026-03-19 10:13 ET
Argenx SE published news for 2025 q4
SEC form 20
2026-03-19 10:13 ET
Argenx SE published news for 2025 q4
SEC form 6
2026-03-19 10:05 ET
Argenx SE published news for 2025 q4
SEC form 6
2026-03-19 10:05 ET
Argenx SE published news for 2025 q4
SEC form 6
2026-03-06 11:15 ET
Argenx SE published news for 2025 q4
SEC form 6
2026-03-06 11:15 ET
Argenx SE published news for 2025 q4
SEC form 6
2026-02-26 08:37 ET
Argenx SE published news for 2025 q4
SEC form 6
2026-02-26 08:37 ET
Argenx SE reported for 2025 q4
SEC form 6
2026-02-26 08:37 ET
Argenx SE reported for 2025 q4
SEC form 6
2026-02-26 08:37 ET
Argenx SE published news for 2025 q4
SEC form 6
2026-02-26 06:20 ET
Argenx SE published news for 2025 q4
SEC form 6
2026-02-26 06:20 ET
Argenx SE published news for 2025 q4
SEC form 6
2026-01-13 11:05 ET
Argenx SE published news for 2025 q4
SEC form 6
2026-01-13 11:05 ET
Argenx SE published news for 2025 q4
SEC form 6
2026-01-12 21:05 ET
Argenx SE published news for 2025 q4
SEC form 6
2026-01-12 21:05 ET
Argenx SE published news for 2025 q4
SEC form 6
2026-01-12 21:05 ET
Argenx SE published news for 2025 q4
SEC form 6
2026-01-05 12:26 ET
Argenx SE published news for 2025 q4
SEC form 6
2026-01-05 12:26 ET
Argenx SE published news for 2025 q4
SEC form 6
2025-12-15 06:15 ET
Argenx SE published news for 2025 q3
SEC form 6
2025-12-15 06:15 ET
Argenx SE published news for 2025 q3
SEC form 6
2025-11-18 17:01 ET
Argenx SE published news for 2025 q3
SEC form 6
2025-11-18 17:01 ET
Argenx SE published news for 2025 q3
SEC form 6
2025-10-30 12:04 ET
Argenx SE published news for 2025 q3
SEC form 6
2025-10-30 12:04 ET
Argenx SE published news for 2025 q3
SEC form 6
2025-10-30 12:04 ET
Argenx SE published news for 2025 q3
SEC form 6
2025-10-29 15:11 ET
Argenx SE published news for 2025 q3
SEC form 6
2025-10-29 15:11 ET
Argenx SE published news for 2025 q3
SEC form 6
2025-10-15 10:05 ET
Argenx SE published news for 2025 q3
SEC form 6
2025-10-15 10:05 ET
Argenx SE published news for 2025 q3
SEC form 6
2025-10-03 16:32 ET
Argenx SE published news for 2025 q3
SEC form 6
2025-10-03 16:32 ET
Argenx SE published news for 2025 q3
SEC form 6
2025-08-25 11:23 ET
Argenx SE published news for 2025 q2
SEC form 6
2025-08-25 11:23 ET
Argenx SE published news for 2025 q2
SEC form 6
2025-07-31 12:16 ET
Argenx SE published news for 2025 q2
SEC form 6
2025-07-31 12:16 ET
Argenx SE published news for 2025 q2
SEC form 6
2025-07-31 12:16 ET
Argenx SE published news for 2025 q2
SEC form 6
2025-07-31 12:16 ET
Argenx SE published news for 2025 q2
SEC form 6
2025-06-30 11:49 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-06-30 11:49 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-06-20 20:05 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-06-20 20:05 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-06-11 10:30 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-06-11 10:30 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-05-28 20:37 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-05-28 20:37 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-05-08 10:39 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-05-08 10:39 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-05-08 10:39 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-04-28 12:06 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-04-28 12:06 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-04-12 00:02 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-04-12 00:02 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-04-11 00:23 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-04-11 00:23 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-04-08 10:05 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-04-08 10:05 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-03-20 10:07 ET
Argenx SE published news for 2024 q4
SEC form 6
2025-03-20 10:07 ET
Argenx SE published news for 2024 q4
SEC form 20
2025-03-20 00:00 ET
Argenx SE published news for 2024 q4
SEC form 20
2025-03-20 00:00 ET
Argenx SE published news for 2024 q4
SEC form 20
2025-03-20 00:00 ET
Argenx SE published news for 2024 q4
SEC form 20
2025-03-20 00:00 ET
Argenx SE published news for 2024 q4
SEC form 20
2025-03-20 00:00 ET
Argenx SE published news for 2024 q4
SEC form 20
2025-03-20 00:00 ET
Argenx SE published news for 2024 q4
SEC form 20
2025-03-20 00:00 ET
Argenx SE published news for 2024 q4
SEC form 20
2025-03-20 00:00 ET
Argenx SE published news for 2024 q4
SEC form 20
2025-03-20 00:00 ET
Argenx SE published news for 2024 q4
SEC form 20
2025-03-20 00:00 ET
Argenx SE published news for 2024 q4
SEC form 20
2025-03-20 00:00 ET
Argenx SE published news for 2024 q4
SEC form 20
2025-03-20 00:00 ET
Argenx SE published news for 2024 q4
SEC form 6
2025-03-07 11:05 ET
Argenx SE published news for 2024 q4
SEC form 6
2025-03-07 11:05 ET
Argenx SE published news for 2024 q4
SEC form 6
2025-02-27 06:34 ET
Argenx SE published news for 2024 q4
SEC form 6
2025-02-27 06:34 ET
Argenx SE reported for 2024 q4
SEC form 6
2025-02-27 06:34 ET
Argenx SE published news for 2024 q4
SEC form 6
2025-02-27 06:34 ET
Argenx SE reported for 2024 q4
SEC form 6
2024-11-20 06:35 ET
Argenx SE published news for 2024 q3
SEC form 6
2024-11-20 06:35 ET
Argenx SE published news for 2024 q3
SEC form 6
2024-11-12 06:35 ET
Argenx SE published news for 2024 q3
SEC form 6
2024-11-12 06:35 ET
Argenx SE published news for 2024 q3
SEC form 6
2024-10-31 08:15 ET
Argenx SE published news for 2024 q3
SEC form 6
2024-10-31 08:15 ET
Argenx SE published news for 2024 q3
SEC form 6
2024-10-31 08:15 ET
Argenx SE published news for 2024 q3
SEC form 6
2024-10-15 08:14 ET
Argenx SE published news for 2024 q3
SEC form 6
2024-10-15 08:14 ET
Argenx SE published news for 2024 q3
SEC form 6
2024-09-19 06:06 ET
Argenx SE published news for 2024 q2
SEC form 6
2024-09-19 06:06 ET
Argenx SE published news for 2024 q2
SEC form 6
2024-07-25 06:01 ET
Argenx SE published news for 2024 q2
SEC form 6
2024-07-25 06:01 ET
Argenx SE reported for 2024 q2
SEC form 6
2024-07-25 06:01 ET
Argenx SE reported for 2024 q2
SEC form 6
2024-07-16 17:22 ET
Argenx SE published news for 2024 q2
SEC form 6
2024-07-16 17:22 ET
Argenx SE published news for 2024 q2
SEC form 6
2024-07-16 16:03 ET
Argenx SE published news for 2024 q2
SEC form 6
2024-07-16 16:03 ET
Argenx SE published news for 2024 q2
SEC form 6
2024-06-25 16:50 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-06-25 16:50 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-06-24 06:05 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-06-24 06:05 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-06-24 06:05 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-06-17 06:05 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-06-17 06:05 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-05-08 06:15 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-05-08 06:15 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-04-16 06:05 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-04-16 06:05 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-03-27 06:14 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-27 06:14 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-27 06:07 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-27 06:07 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-27 06:07 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-27 06:07 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-27 06:07 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-27 06:07 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-26 06:05 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-26 06:05 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-21 06:07 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-21 06:07 ET
Argenx SE published news for 2023 q4
SEC form 20
2024-03-21 00:00 ET
Argenx SE published news for 2023 q4
SEC form 20
2024-03-21 00:00 ET
Argenx SE published news for 2023 q4
SEC form 20
2024-03-21 00:00 ET
Argenx SE published news for 2023 q4
SEC form 20
2024-03-21 00:00 ET
Argenx SE published news for 2023 q4
SEC form 20
2024-03-21 00:00 ET
Argenx SE published news for 2023 q4
SEC form 20
2024-03-21 00:00 ET
Argenx SE published news for 2023 q4
SEC form 20
2024-03-21 00:00 ET
Argenx SE published news for 2023 q4
SEC form 20
2024-03-21 00:00 ET
Argenx SE published news for 2023 q4
SEC form 20
2024-03-21 00:00 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-02-29 16:04 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-02-29 16:04 ET
Argenx SE reported for 2023 q4
SEC form 6
2024-02-29 16:04 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-02-29 16:04 ET
Argenx SE reported for 2023 q4
SEC form 6
2024-02-20 06:06 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-02-20 06:06 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-01-18 06:10 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-01-18 06:10 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-01-08 06:06 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-01-08 06:06 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-01-08 06:06 ET
Argenx SE published news for 2023 q4
SEC form 6
2023-11-01 16:01 ET
Argenx SE published news for 2023 q3
SEC form 6
2023-10-31 09:14 ET
Argenx SE published news for 2023 q3
SEC form 6
2023-09-21 08:38 ET
Argenx SE published news for 2023 q2
SEC form 6
2023-07-27 06:02 ET
Argenx SE reported for 2023 q2
SEC form 6
2023-07-20 17:44 ET
Argenx SE published news for 2023 q2
SEC form 6
2023-07-17 07:56 ET
Argenx SE published news for 2023 q2
SEC form 6
2023-06-30 16:02 ET
Argenx SE published news for 2023 q1
SEC form 6
2023-06-21 08:52 ET
Argenx SE published news for 2023 q1
SEC form 6
2023-05-05 08:05 ET
Argenx SE published news for 2023 q1
SEC form 6
2023-05-05 08:03 ET
Argenx SE published news for 2023 q1
SEC form 6
2023-04-18 08:44 ET
Argenx SE published news for 2023 q1
SEC form 6
2023-03-16 16:26 ET
Argenx SE reported for 2022 q4
SEC form 6
2023-03-16 08:21 ET
Argenx SE published news for 2022 q4
SEC form 20
2023-03-16 00:00 ET
Argenx SE published news for 2022 q4
SEC form 6
2023-03-02 08:56 ET
Argenx SE reported for 2022 q4
SEC form 6
2023-01-30 08:00 ET
Argenx SE published news for 2022 q4
SEC form 6
2023-01-27 09:28 ET
Argenx SE published news for 2022 q4
SEC form 6
2023-01-09 16:01 ET
Argenx SE published news for 2022 q4
SEC form 6
2022-12-12 16:01 ET
Argenx SE published news for 2022 q3
SEC form 6
2022-11-30 16:02 ET
Argenx SE published news for 2022 q3
SEC form 6
2022-11-22 08:36 ET
Argenx SE published news for 2022 q3
SEC form 6
2022-10-27 08:38 ET
Argenx SE published news for 2022 q3
SEC form 6
2022-09-21 07:39 ET
Argenx SE published news for 2022 q2
SEC form 6
2022-09-08 16:07 ET
Argenx SE published news for 2022 q2
SEC form 6
2022-08-12 08:19 ET
Argenx SE published news for 2022 q2
SEC form 6
2022-07-28 00:00 ET
Argenx SE reported for 2022 q2
SEC form 6
2022-06-27 06:00 ET
Argenx SE published news for 2022 q1
SEC form 6
2022-05-19 16:30 ET
Argenx SE published news for 2022 q1
SEC form 6
2022-05-05 07:53 ET
Argenx SE published news for 2022 q1
SEC form 6
2022-03-25 16:23 ET
Argenx SE published news for 2021 q4
SEC form 6
2022-03-22 09:22 ET
Argenx SE published news for 2021 q4
SEC form 6
2022-03-21 12:56 ET
Argenx SE published news for 2021 q4
SEC form 20
2022-03-21 00:00 ET
Argenx SE published news for 2021 q4
SEC form 6
2022-03-03 06:06 ET
Argenx SE published news for 2021 q4
SEC form 6
2022-01-20 08:12 ET
Argenx SE published news for 2021 q4
SEC form 6
2022-01-10 07:22 ET
Argenx SE published news for 2021 q4
SEC form 6
2022-01-07 07:27 ET
Argenx SE published news for 2021 q4
SEC form 6
2021-12-22 16:12 ET
Argenx SE published news for 2021 q3
SEC form 6
2021-07-29 00:00 ET
Argenx SE published news for 2021 q2
SEC form 6
2021-06-07 16:02 ET
Argenx SE published news for 2021 q1
SEC form 6
2021-06-01 16:02 ET
Argenx SE published news for 2021 q1
SEC form 6
2021-05-14 07:39 ET
Argenx SE published news for 2021 q1
SEC form 6
2021-05-11 16:08 ET
Argenx SE published news for 2021 q1
SEC form 6
2021-03-30 16:55 ET
Argenx SE published news for 2020 q4
SEC form 6
2021-03-30 16:48 ET
Argenx SE published news for 2020 q4
SEC form 6
2021-02-04 16:51 ET
Argenx SE published news for 2020 q4
SEC form 6
2021-02-01 08:58 ET
Argenx SE published news for 2020 q4
SEC form 6
2021-01-08 07:07 ET
Argenx SE published news for 2020 q4
SEC form 6
2021-01-06 16:07 ET
Argenx SE published news for 2020 q4
SEC form 6
2020-11-23 08:45 ET
Argenx SE published news for 2020 q3
SEC form 6
2020-10-22 06:01 ET
Argenx SE published news for 2020 q3
SEC form 6
2020-10-06 07:54 ET
Argenx SE published news for 2020 q3